Advertisement
Advertisement
U.S. Markets open in 6 hrs 28 mins
Advertisement
Advertisement
Advertisement
Advertisement

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.05+0.52 (+2.04%)
At close: 04:00PM EST
26.05 0.00 (0.00%)
After hours: 04:15PM EST
Advertisement
Sign in to post a message.
  • Y
    Yahoo Finance Insights
    Myriad Genetics is up 5.60% to 26.42
  • Y
    Yahoo Finance Insights
    Myriad Genetics is up 5.62% to 26.30
  • K
    Katina
    I'm happy to join those who are sharing the good news about Mr Grey I'm not persuading anyone to trade with him but I advice every investor to make the right choice with grey got my withdrawal safely without any interruption. Contact him and you will get more profit.. via Telegram @greywayne
  • A
    Alloro
    And there it is: Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer
    https://finance.yahoo.com/news/prolaris-test-accurately-predicts-risk-112857407.html
    SALT LAKE CITY, June 27, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of results from a large study that.
    SALT LAKE CITY, June 27, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of results from a large study that.
    finance.yahoo.com
  • s
    stockrobot
    Morgan Stanley upgraded with $55 PT.
  • D
    D
    Myriad announced today that UnitedHealthcare has issued a positive coverage decision for pharmacogenetic testing for multi-gene panels including the company’s GeneSight Psychotropic test. The coverage is for patients that have a diagnosis of major depressive disorder or anxiety and have failed at least one prior medication to treat their condition. The positive coverage decision is referenced in the UnitedHealthcare August 2019 Network Bulletin.
  • b
    bennett
    Times are tough right now internally for Myriad (1) Hiring freeze for 90 days (2) leadership team across the board takes 30% reduction in salaries until further notice. (3)Bonuses / commission for ALL employees that qualify will take a 50% reduction in the 4th Qtr!
  • A
    Allez les bleu
    anyone else following this stock besides me? big announcement today, looks like a great addition to an already strong product line. your thoughts?
  • C
    Chevy
    FYI: they gave the new CEO 1.3MM shares as part of his hiring package. must be nice. at $13.38 (702,888) and $12.33 (597,908).
  • D
    Dragan
    What is going on? Some good news?.....
  • M
    Mike
    3 day rule.. I am a buyer at 17.50 if it hits that number before 3 days. If not I will buy on Thursday. I dodged a pretty big bullet today. I had 2k at 25 and sold at 34. Whew!
  • A
    Allez les bleu
    MYGN is looking poised for another 10% leg up! Thumbs up if you agree!
  • b
    bennett
    After working for Myriad for 8 years, it continues to boggle my brain why the stock is not performing better. The two markets that are performing very well were acquired not organically grown. The Hereditary space has been impacted by companies with weaker data but it amazes me that they are still reimbursed by the same payers. Not a great trend! Ever since Myriad lost their Supreme Court case, Wall Street seems to have less faith in management based on the current stock price. Indication that maybe a leadership change is needed.
    Neutral
  • Y
    Yahoo Finance Insights
    MYGN reached a new 52 Week High at 39.10
  • K
    Kent
    Most of the breakthroughs in medicine of the future will be because of genetics. MYGN at under $2B mkt cap is a gift with its multitude of products. Compare that to EXAS with only one inaccurate expensive product, testing stools, yet the stock has a mkt cap of over $10B.
  • A
    Alloro
    Bill Alpert's article on Barrons makes me suspect the timing. It was released 7:26 pm on Friday night. Was it's release held until then to prevent price crash?
  • v
    victor
    Cup and handle breakout emanate!
  • K
    Kent
    Buying MYGN , is like buying EXAS for $12.40, which is in the same screening business. MYGN does not have the risk of Cologuard guard and Covid testing, both over priced tests, going obsolete.
  • M
    Michael T
    What’s the run today?
  • v
    victor
    Not sure if Goldman realizes MYGN is now the only FDA approved for BRAC. See you later fly by night labs. You need Myriad’s data base to make accurate decisions. Who wants efficacy rates of 40-60%. This is a live and death decision. Who doesn’t like 99% accuracy!
Advertisement
Advertisement